全文获取类型
收费全文 | 274篇 |
免费 | 14篇 |
专业分类
儿科学 | 1篇 |
基础医学 | 18篇 |
口腔科学 | 2篇 |
临床医学 | 28篇 |
内科学 | 81篇 |
皮肤病学 | 72篇 |
神经病学 | 24篇 |
特种医学 | 1篇 |
外科学 | 31篇 |
预防医学 | 1篇 |
药学 | 4篇 |
肿瘤学 | 25篇 |
出版年
2022年 | 2篇 |
2021年 | 6篇 |
2020年 | 6篇 |
2019年 | 2篇 |
2018年 | 4篇 |
2017年 | 2篇 |
2016年 | 3篇 |
2015年 | 8篇 |
2014年 | 4篇 |
2013年 | 6篇 |
2012年 | 13篇 |
2011年 | 7篇 |
2010年 | 5篇 |
2009年 | 8篇 |
2008年 | 10篇 |
2007年 | 11篇 |
2006年 | 15篇 |
2005年 | 16篇 |
2004年 | 10篇 |
2003年 | 17篇 |
2002年 | 11篇 |
2001年 | 14篇 |
2000年 | 8篇 |
1999年 | 9篇 |
1998年 | 6篇 |
1997年 | 3篇 |
1996年 | 3篇 |
1995年 | 2篇 |
1994年 | 3篇 |
1993年 | 4篇 |
1992年 | 12篇 |
1991年 | 12篇 |
1990年 | 10篇 |
1989年 | 9篇 |
1988年 | 6篇 |
1987年 | 8篇 |
1986年 | 4篇 |
1985年 | 4篇 |
1984年 | 5篇 |
排序方式: 共有288条查询结果,搜索用时 15 毫秒
1.
Best-practice algorithms for the use of a bilayered living cell therapy (Apligraf® ) in the treatment of lower-extremity ulcers 总被引:1,自引:0,他引:1
Joseph Cavorsi MD FACS ; Frank Vicari MD FACS FAAP ; Douglas J. Wirthlin MD FACS ; William Ennis DO MBA FACOS ; Robert Kirsner MD ; Sean M. O''Connell PhD ; John Steinberg DPM ; Vincent Falanga MD 《Wound repair and regeneration》2006,14(2):102-109
Tissue-engineered skin substitutes such as Apligraf have emerged over the past 20 years as among the most carefully studied and efficacious of the advanced wound modalities. These products have been proven as effective enhancements to general wound care, promoting wound closure particularly in instances where conventional wound care fails. Marketed for hard-to-heal wounds since 1998, Apligraf has become part of standard wound care in many wound centers across the United States. Despite this situation, few general wound care guidelines incorporate advanced and active wound-healing technologies, such as tissue-engineered skin products. Because of this deficiency, appropriate patient selection and proper use of these product remain largely unaddressed within the general wound care community. Here, we describe the development of guidelines surrounding optimal use of the bilayered living cell therapy, Apligraf, in the treatment of the two types of lower extremity ulcers for which the product is FDA approved: venous leg ulcer and diabetic foot ulcer. The guidelines detailed in this article focus on the identification and selection of patients who are at risk for failure of standard wound care therapy and thus appropriate for Apligraf treatment. The intended audience for these guidelines is the general wound care practitioner, for whom the developed treatment algorithms and accompanying figure legends should provide practical, user-friendly direction simplifying both patient selection and appropriate use of Apligraf within the context of good wound-healing practice. 相似文献
2.
V Falanga R Kirsner M H Katz E Gould W H Eaglstein S McFalls 《The Journal of dermatologic surgery and oncology》1992,18(5):409-414
A recent hypothesis suggests that venous hypertension leads to ulceration through the formation of pericapillary fibrin cuffs, which are presumed to impede the exchange of oxygen and other nutrients. In this report, we evaluated by direct immunofluorescence the presence of pericapillary fibrin at the edge of venous ulcers during the course of treatment with elastic compression. In an initial group of 23 patients studied at baseline, pericapillary fibrin cuffs were detected in 20 (91%) of 22 patients. The intensity of fibrin staining, rated blindly on a scale of 0 to 3, could not be correlated with several baseline parameters, including the clinical presence and extent of lipodermatosclerosis, ulcer size, venous recovery time, and transcutaneous oxygen measurements (TcPO2) taken next to the ulcer. Eleven of this initial group of 23 patients were randomly selected to receive elastic compression treatment, and were evaluated for the persistence of pericapillary fibrin at 60 and 120 days. Although a reduction (mean +/- SD = 50.2% +/- 25.7) in ulcer size occurred in 10 of the 11 patients, pericapillary fibrin was still present at the ulcer edge and with undiminished intensity. We conclude that pericapillary fibrin cuffs in venous ulcers persist with compression treatment and in spite of healing, and are unlikely to be directly related to the development of ulceration. 相似文献
3.
4.
Livneh Nir Braeken Dionne Drozdinsky Genady Gafter-Gvili Anat Seelig Jaap Rozovski Uri Berger Tamar Raanani Pia Falanga Anna ten Cate Hugo Spectre Galia Leader Avi 《Journal of thrombosis and thrombolysis》2021,52(2):590-596
Journal of Thrombosis and Thrombolysis - Managing anticoagulation in hematological malignancy patients with atrial fibrillation and thrombocytopenia is a clinical challenge with limited data. We... 相似文献
5.
6.
Cancer procoagulant in acute lymphoblastic leukemia 总被引:1,自引:0,他引:1
M G Alessio A Falanga R Consonni R Bassan B Minetti M B Donati T Barbui 《European journal of haematology》1990,45(2):78-81
In a previous study we characterized cancer procoagulant (CP), a 68 kd cysteine proteinase which directly activates coagulation factor X in various subtypes (from M1 to M5) of acute non-lymphoblastic leukemia (ANLL). The aim of this study was to determine whether CP is also expressed by acute lymphoblastic leukemia (ALL) cells. Blasts from 25 ALL patients were extracted and tested for their procoagulant properties. 16 samples (64%) shortened the recalcification time of normal human plasma, and 9 (36%) did not. 8 of the 16 active samples showed properties compatible with CP, i.e. independence from factor VII in triggering blood coagulation and sensitivity to cysteine proteinase inhibitors. Selected samples also cross-reacted with a polyclonal antibody raised against purified CP. The specific activity of CP in ALL extracts was significantly lower than in most ANLL types previously studied (all but M4). These finding indicate that CP can be a property of the lymphoid phenotype although its expression may be lower than in the myeloid phenotype. 相似文献
7.
Galdiero Emilia Siciliano Antonietta Lombardi Lucia Falanga Annarita Galdiero Stefania Martucci Francesca Guida Marco 《Ecotoxicology (London, England)》2020,29(2):156-162
Ecotoxicology - Nanomaterials have revolutionized many scientific fields and are widely applied to address environmental problems and to develop novel health care strategies. However, their... 相似文献
8.
All-trans-retinoic acid counteracts endothelial cell procoagulant activity induced by a human promyelocytic leukemia-derived cell line (NB4) 总被引:3,自引:0,他引:3
Therapy with all-trans-retinoic acid (ATRA) can rapidly improve the coagulopathy of acute promyelocytic leukemia (APL). This study was designed to evaluate whether the APL cell line NB4 induces the procoagulant activity (PCA) of human endothelial cells (ECs) in vitro, and whether this property is modified after ATRA-induced NB4 maturation. EC monolayers were incubated for 4 hours at 37 degrees C with the conditioned media (CM) of NB4 treated with 1 mumol/L ATRA (ATRA-NB4-CM) or the vehicle (control-NB4-CM). EC lysates were tested for PCA. ATRA-NB4-CM induced significantly more PCA:tissue factor (TF) than control-NB4-CM (P < .01). To identify the cause of TF induction, interleukin (IL)-1 beta antigen levels were measured in CM samples. ATRA-NB4-CM contained significantly more IL-1 beta than control-NB4-CM. EC PCA was significantly inhibited by an anti-IL-1 beta antibody. The addition to the media of 10 mumol/L ATRA counteracted the EC TF expression induced by NB4-CM. These data indicate that ATRA increases the promyelocyte-induced EC TF, partly through increased IL-1 beta production. However, ATRA can protect the endothelium from the procoagulant stimulus of leukemic cells. 相似文献
9.
10.